Sydney, Oct 16, 2007 (ABN Newswire) - Stirling Products Limited (ASX: STI) advises shareholders that studies recently conducted at the University of Western Australia have confirmed the superior biological potency of R-salbutamol over racemic salbutamol.
The biological potency of bronchodilators (of which racemic (mixed) salbutamol and the more refined R-salbutamol are examples) is most commonly assessed by measuring relaxation responses in tracheal tissue. Stirling has recently completed studies on its new raw material manufactured under a patented process in Europe. These studies confirm R-salbutamol is twice as potent as racemic salbutamol.
"The studies compared the biological activity from our most recent batch of R-salbutamol manufactured in Europe under Stirling's patented process with racemic salbutamol and a leading industry standard used in human pharmaceutical preparations", indicated Dr London, CEO and Managing Director, Stirling Products.
In vitro dose-response testing, performed in the Pharmacology and Anaesthesiology Unit of the University of Western Australia by Dr Peter Henry, demonstrated that Stirling's R-salbutamol was twice as potent as racemic salbutamol. That is, it produces the same response at half the dose. The results also indicated there was no measurable difference in potency or activity between Stirling R-salbutamol and the industry control widely used in human pharmaceuticals.
"These results produced a better than expected result for the biological activity of R-salbutamol. R-salbutamol, because of its 'chemical purity', produces a superior potency profile than racemic (mixed) salbutamol and it is as good as, if not better than, product currently manufactured by other processes and used in humans", indicated Dr London. "This is in essence, a validation of the manufacturing process and the product that is produced. It gives us continued confidence that the positive results we are seeing in all our trials are real, whether used as a growth agent in livestock, as a treatment for overweight dogs or as a treatment to relieve the symptoms of heaves in horses'.
The R-salbutamol that was tested is being used for the trials, currently being conducted by Merial Limited, for use as a growth agent in sheep and potentially cattle.
The biological potency of bronchodilators (of which racemic (mixed) salbutamol and the more refined R-salbutamol are examples) is most commonly assessed by measuring relaxation responses in tracheal tissue. Stirling has recently completed studies on its new raw material manufactured under a patented process in Europe. These studies confirm R-salbutamol is twice as potent as racemic salbutamol.
"The studies compared the biological activity from our most recent batch of R-salbutamol manufactured in Europe under Stirling's patented process with racemic salbutamol and a leading industry standard used in human pharmaceutical preparations", indicated Dr London, CEO and Managing Director, Stirling Products.
In vitro dose-response testing, performed in the Pharmacology and Anaesthesiology Unit of the University of Western Australia by Dr Peter Henry, demonstrated that Stirling's R-salbutamol was twice as potent as racemic salbutamol. That is, it produces the same response at half the dose. The results also indicated there was no measurable difference in potency or activity between Stirling R-salbutamol and the industry control widely used in human pharmaceuticals.
"These results produced a better than expected result for the biological activity of R-salbutamol. R-salbutamol, because of its 'chemical purity', produces a superior potency profile than racemic (mixed) salbutamol and it is as good as, if not better than, product currently manufactured by other processes and used in humans", indicated Dr London. "This is in essence, a validation of the manufacturing process and the product that is produced. It gives us continued confidence that the positive results we are seeing in all our trials are real, whether used as a growth agent in livestock, as a treatment for overweight dogs or as a treatment to relieve the symptoms of heaves in horses'.
The R-salbutamol that was tested is being used for the trials, currently being conducted by Merial Limited, for use as a growth agent in sheep and potentially cattle.
| Tweet |
About Stirling Products Limited
Stirling Products is developing patented animal growth agents that increase meat production, therefore improving the production efficiency of livestock animals, while decreasing fat accumulation for the benefit of consumers. The Stirling growth agents are under development for swine, poultry, cattle and sheep for global markets and are being positioned to take a major role in reducing the global use of antibiotics and steroid hormones in livestock. Stirling is also developing veterinary medications for heaves in horses through its joint venture in Europe (Pulmovet ApS, www.pulmovet.com) and an obesity treatment in companion animals.
Stirling Products recently acquired a Canadian company Progressive BioActives Incorporated (PBI) under its North American subsidiary, Stirling Products NA Inc. PBI is part of the Bioscience cluster established on located Prince Edward Island, Canada. PBI's lead product ProVale, is the latest high purity beta glucan extract that has been designed as an alternative tool for sustainable livestock management in face of increasing viral disease challenges where antibiotics have no or limited application. ProVale is available for targeted applications in swine, poultry and farmed aquaculture with a future focus on further developing applications for companion animals (e.g. horses, dogs, cats and reptiles).
|
||
|
 |
Related Companies |
>>> Stirling Products Limited |
| |
Related Industry Topics: |
Clinical Trials | Ag Biotechnology | |
| |
This Page Viewed: (Last 7 Days: 20) (Last 30 Days: 70) (Since Published: 9510) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
